SCHEMBL1752604

SCHEMBL1752604

CN[C@H](C)C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3132758 1.00
SCHEMBL742837 1.00
Hydrochloric Acid SCHEMBL30461951 0.97
Hydrochloric Acid SCHEMBL5565250 0.82
SCHEMBL28825344 0.74
SCHEMBL10420937 0.74 ADH1B (0.37)
SCHEMBL23635220 0.73
SCHEMBL19220821 0.73
Isobutyraldehyde SCHEMBL2635854 0.71 ADH1B (0.38)
Isobutyraldehyde SCHEMBL788159 0.71 ADH1B (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195898-A1 TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS VOYAGER PHARMACEUTICAL CORPORATION (US) 2011-08-11 US claimed
US-20100173838-A1 NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES VISKOV CHRISTIAN 2010-07-08 US claimed
EP-1451209-A4 TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2009-06-03 EP claimed
EP-1450840-A4 DI-, TRI,- AND TETRA-PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2009-06-03 EP claimed
US-20080171736-A1 Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists VOYAGER PHARMACEUTICAL CORPORATION 2008-07-17 US claimed
US-20080071062-A1 TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY HAVIV FORTUNA 2008-03-20 US claimed
EP-1461356-A4 HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2007-12-12 EP claimed
US-20070213260-A1 Novel process for the preparation of cyclosporin derivatives AVENTIS PHARMA S.A. 2007-09-13 US claimed
US-20070167376-A1 Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity HAVIV FORTUNA 2007-07-19 US claimed
US-7169888-B2 Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity ABBOTT LABORATORIES (US) 2007-01-30 US claimed
US-4885276-A IMMUNOSUPPRESSIVE AGENTS WITH DECREASED TOXICITY MERCK & CO., INC. (US) 1989-12-05 US claimed
WO-1989007450-A1 LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 WO claimed
EP-0328090-A2 LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 EP claimed
US-4798823-A IMMUNOSUPPRESSIVE AGENTS MERCK & CO., INC. (US) 1989-01-17 US claimed
US-4775660-A Treatment of breast cancer by combination therapy LABRIE FERNAND (CA) 1988-10-04 US claimed
US-4760053-A Combination therapy for selected sex steroid dependent cancers LABRIE FERNAND (CA) 1988-07-26 US claimed
US-4659695-A Method of treatment of prostate cancer LABRIE FERNAND (CA) 1987-04-21 US claimed
EP-0195015-A1 PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS. LABRIE FERNAND (CA) 1986-09-24 EP claimed
EP-0188214-A2 Novel growth hormone-releasing peptides and method of treating mammals therewith The Administrators of The Tulane University Educational Fund (US) 1986-07-23 EP claimed
WO-1986001105-A1 PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS LABRIE FERNAND (CA) 1986-02-27 WO claimed